Next generation solutions for the global fight against AMR.
Ares Genetics, an OpGen Group Company, is revolutionizing how we address the global challenge of antimicrobial resistance (AMR). To enable better infection control and more targeted patient care, Ares Genetics aims to provide unprecedented insight into AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Innovative machine learning driven bioinformatics and the extensively curated ARESdb database comprehensively detect and interpret the genetic profile of pathogens.
Unlike conventional molecular assays, Ares Genetics solutions not only detect AMR markers but shed light on prevalence and diagnostic performance for these markers and predict how pathogens will respond to therapy.
Ares Genetics offers a portfolio of services and solutions for outbreak surveillance, infection control, AMR prediction, and the targeted delivery of antimicrobial therapy.
To enable labs globally, Ares has developed the AREScloud, a user-friendly bioinformatics and reporting hub powered by ARESdb.
ARESdb is a database of AMR biomarkers comprehensively covering resistance genes and mutations. Unlike other databases, ARESdb informs on the diagnostic performance of AMR markers and enables the AI-powered prediction of phenotypic resistance (predictive AST) directly from genome data.
Ares Genetics solutions also include isolate sequencing services (ARESiss), the culture-free universal pathogenome assay (ARESupa) comprehensively screening for pathogen and AMR markers, ARESdb, AREScloud, as well as tailored bioinformatics services.